Vol.

No.

February 14, 2020Feb 14, 2020

DOWNLOAD THE PDF

Cover Story

Sharpless addresses three big issues in cancer in 2020:

1. NCI grantees are prime targets for foreign influence, 2. Treatment seems to drive drop in lung cancer deaths, 3. RPG paylines to rise from 8% to 10%

By Matthew Bin Han Ong

The pace of innovation in oncology has made U.S. cancer researchers prime targets for foreign state-sponsored programs aimed at diverting intellectual property.

Thomas Sellers sues Moffitt, claims defamation

By Matthew Bin Han Ong

Free

Trump's budget proposes slashing NIH, NCI

By Alexandria Carolan

Clinical

Ohio State expands assistance program to give out previously dispensed cancer drugs

By Alexandria Carolan

In Brief

Jeff Boyd named chief scientific officer at Northwell Health

Colleen McBride named associate director at Winship

Zelia Correa named co-director of ocular oncology service at Sylvester and Bascom Palmer Eye Institute

Karyn Aalami Goodman named associate director for clinical research at The Tisch Cancer Institute at Mount Sinai

Lillian Siu receives TAT 2020 Honorary Award for cancer drug development

Funding Opportunities

NETRF awards $3.5M to advance neuroendocrine tumor treatment

Clinical Roundup

City of Hope Triplex vaccine reduces rate of CMV complications in transplant recipients by half

Study: Radiation therapy for soft tissue sarcoma can be cut from five weeks to five days

Keytruda meets PFS endpoint in TNBC study

Xtandi demonstrates significant improvement in OS in nmCRPC

Vape users show chemical changes in their genome linked to cancer

Drugs & Targets

FDA approves Pemfexy injection for lung cancer

FDA grants Priority Review for BMS agent lisocabtagene maraleucel

FDA grants Priority Review for Seattle Genetics agent tucatinib

FDA grants Nanobiotix Fast Track designation for investigation of NBTXR3 in head and neck

Myriad submits sPMA for myChoice CDx with Lynparza in first-line maintenance therapy in advanced ovarian cancer

PREVIOUS ISSUE

NEXT ISSUE